drugset
Drugs / Y-90 Resin Microspheres
last change Jul 2026 re-read 3 minutes ago

Y-90 Resin Microspheres

Trials 0

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Comparator or background therapy1 trial
Phase 2 NCT05377034 Background Oct 2022 → Jul 2026 overdue hepatocellular carcinoma National Cancer Centre, Singapore Recruiting No outcome recorded

Press releases naming this drug 14 releases

DateIssuerRelease
2025-09-08 Sirtex Medical Sirtex Receives Expanded CE Mark Approval for SIR-Spheres® Y-90 Resin Microspheres sirtex.com ↗
2025-07-07 Sirtex Medical Sirtex Medical’s SIR-Spheres ® Y-90 Resin Microspheres Receive FDA Approval for the Treatment of Unresectable Hepatocellular Carcinoma sirtex.com ↗
2024-09-16 Sirtex Medical Sirtex Medical Announces Certification of SIR-Spheres® Y-90 Resin Microspheres According to Medical Device Regulation (EU) 2017/745 and European Launch of the Innovative SIROS™ Delivery System sirtex.com ↗
2022-02-09 Sirtex Medical Sirtex Medical and Grand Pharmaceutical Group Limited receive NDA approval of SIR-Spheres ® Y-90 resin microspheres in China from the National Medical Products Administration sirtex.com ↗
2021-10-11 Sirtex Medical Sirtex Medical and China Grand Pharmaceutical announce successful first administration of SIR-Spheres ® Y-90 resin microspheres in China sirtex.com ↗
2020-11-25 Sirtex Medical Sirtex Medical and China Grand Pharmaceutical announce SIR-Spheres ® Y-90 resin microspheres milestone sirtex.com ↗
2019-06-24 Sirtex Medical Sirtex Medical reaches milestone 100,000th patient dose delivery of SIR-Spheres ® Y-90 resin microspheres PDF Languages sirtex.com ↗
2017-07-03 Sirtex Medical New Analysis Reveals First-Line Treatment Data on SIR-Spheres ® Y-90 Resin Microspheres for Patients with Liver Metastases from Right-Sided Primary Colon Cancer sirtex.com ↗
2017-06-05 Sirtex Medical SIR-Spheres ® Y-90 Resin Microspheres Showed no Significant Difference in Overall Survival (OS) Compared to Sorafenib in Advanced HCC with Significantly Fewer Severe Adverse Events, New Asia-Pacific Study Finds PDF Languages sirtex.com ↗
2017-05-24 Sirtex Medical Metastatic colorectal cancer patients treated first-line with SIR-Spheres ® Y-90 resin microspheres more likely to become candidates for potentially curative liver surgery, REsect study shows PDF Languages sirtex.com ↗
2016-12-12 Sirtex Medical NCCN Guidelines® Recommend SIR-Spheres ® Y-90 Resin Microspheres for the Treatment of Metastatic Colorectal Cancer sirtex.com ↗
2016-10-06 Sirtex Medical Liver Cancer Researchers from AP-HP and Singapore Collaborate on a Prospective Meta-Analysis of Two Studies of Y-90 resin microspheres versus Sorafenib in Patients with Unresectable Hepatocellular Carcinoma (HCC) PDF Languages sirtex.com ↗

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Y-90 Resin Microspheres “Selective Internal Radiation Therapy (Y-90 Resin Microspheres)” NCT05377034 ↗